nodes	percent_of_prediction	percent_of_DWPC	metapath
Dinoprostone—HPGDS—testicular cancer	0.536	1	CbGaD
Dinoprostone—SLCO1A2—Chlorambucil—testicular cancer	0.0603	0.193	CbGbCtD
Dinoprostone—SLCO3A1—Methotrexate—testicular cancer	0.049	0.157	CbGbCtD
Dinoprostone—ABCC5—Cisplatin—testicular cancer	0.0482	0.154	CbGbCtD
Dinoprostone—SLCO1C1—Methotrexate—testicular cancer	0.0313	0.1	CbGbCtD
Dinoprostone—SLC22A2—Vinblastine—testicular cancer	0.0184	0.0589	CbGbCtD
Dinoprostone—SLC22A2—Cisplatin—testicular cancer	0.0169	0.054	CbGbCtD
Dinoprostone—SLC22A11—Methotrexate—testicular cancer	0.0162	0.0517	CbGbCtD
Dinoprostone—SLC22A7—Methotrexate—testicular cancer	0.0154	0.0492	CbGbCtD
Dinoprostone—ABCC4—Methotrexate—testicular cancer	0.015	0.0481	CbGbCtD
Dinoprostone—SLCO1A2—Methotrexate—testicular cancer	0.0108	0.0345	CbGbCtD
Dinoprostone—PTGFR—corpus luteum—testicular cancer	0.0103	0.153	CbGeAlD
Dinoprostone—SLCO1B1—Methotrexate—testicular cancer	0.0102	0.0326	CbGbCtD
Dinoprostone—SLC22A8—Methotrexate—testicular cancer	0.0094	0.0301	CbGbCtD
Dinoprostone—CYP11A1—corpus luteum—testicular cancer	0.00786	0.116	CbGeAlD
Dinoprostone—PTGER2—Ovarian Infertility Genes—DAZL—testicular cancer	0.00717	0.197	CbGpPWpGaD
Dinoprostone—CYP11A1—seminiferous tubule of testis—testicular cancer	0.00666	0.0987	CbGeAlD
Dinoprostone—SLC22A6—Methotrexate—testicular cancer	0.00655	0.0209	CbGbCtD
Dinoprostone—CYP19A1—corpus luteum—testicular cancer	0.00511	0.0757	CbGeAlD
Dinoprostone—CYP1A2—Etoposide—testicular cancer	0.00505	0.0161	CbGbCtD
Dinoprostone—CYP19A1—seminiferous tubule of testis—testicular cancer	0.00433	0.0641	CbGeAlD
Dinoprostone—Dinoprost Tromethamine—HPGDS—testicular cancer	0.00253	1	CrCbGaD
Dinoprostone—CYP19A1—Ovarian Infertility Genes—DAZL—testicular cancer	0.00242	0.0665	CbGpPWpGaD
Dinoprostone—CYP19A1—semen—testicular cancer	0.00239	0.0355	CbGeAlD
Dinoprostone—PTGER4—G alpha (s) signalling events—INSL3—testicular cancer	0.00129	0.0354	CbGpPWpGaD
Dinoprostone—HPGDS—embryo—testicular cancer	0.00118	0.0175	CbGeAlD
Dinoprostone—SLC51B—testis—testicular cancer	0.00108	0.016	CbGeAlD
Dinoprostone—SLC51A—gonad—testicular cancer	0.00107	0.0159	CbGeAlD
Dinoprostone—PTGER2—G alpha (s) signalling events—INSL3—testicular cancer	0.00106	0.0291	CbGpPWpGaD
Dinoprostone—PTGER2—female gonad—testicular cancer	0.000906	0.0134	CbGeAlD
Dinoprostone—PTGER4—female gonad—testicular cancer	0.000889	0.0132	CbGeAlD
Dinoprostone—PTGER1—female gonad—testicular cancer	0.000859	0.0127	CbGeAlD
Dinoprostone—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000855	0.0235	CbGpPWpGaD
Dinoprostone—PTGER2—testis—testicular cancer	0.000803	0.0119	CbGeAlD
Dinoprostone—HPGDS—gonad—testicular cancer	0.000801	0.0119	CbGeAlD
Dinoprostone—SLCO3A1—seminal vesicle—testicular cancer	0.000797	0.0118	CbGeAlD
Dinoprostone—SLCO2A1—seminal vesicle—testicular cancer	0.000789	0.0117	CbGeAlD
Dinoprostone—PTGER4—testis—testicular cancer	0.000788	0.0117	CbGeAlD
Dinoprostone—SLCO2A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00078	0.0214	CbGpPWpGaD
Dinoprostone—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000775	0.0213	CbGpPWpGaD
Dinoprostone—SLC51A—testis—testicular cancer	0.000775	0.0115	CbGeAlD
Dinoprostone—PTGER3—female gonad—testicular cancer	0.000753	0.0111	CbGeAlD
Dinoprostone—SLCO3A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000739	0.0203	CbGpPWpGaD
Dinoprostone—SLCO4A1—seminal vesicle—testicular cancer	0.000726	0.0108	CbGeAlD
Dinoprostone—PTGIR—G alpha (s) signalling events—INSL3—testicular cancer	0.000714	0.0196	CbGpPWpGaD
Dinoprostone—SLCO4A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000705	0.0194	CbGpPWpGaD
Dinoprostone—PTGER3—testis—testicular cancer	0.000668	0.00989	CbGeAlD
Dinoprostone—PTGIR—gonad—testicular cancer	0.000653	0.00967	CbGeAlD
Dinoprostone—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000652	0.0179	CbGpPWpGaD
Dinoprostone—HPGDS—female gonad—testicular cancer	0.000651	0.00964	CbGeAlD
Dinoprostone—ABCC5—NRF2 pathway—SLC2A6—testicular cancer	0.00065	0.0179	CbGpPWpGaD
Dinoprostone—PTGER4—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000613	0.0169	CbGpPWpGaD
Dinoprostone—PTGFR—female gonad—testicular cancer	0.000602	0.00891	CbGeAlD
Dinoprostone—SLCO1C1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000591	0.0163	CbGpPWpGaD
Dinoprostone—PTGER2—lymph node—testicular cancer	0.000582	0.00862	CbGeAlD
Dinoprostone—HPGDS—testis—testicular cancer	0.000577	0.00855	CbGeAlD
Dinoprostone—SLCO3A1—gonad—testicular cancer	0.000576	0.00853	CbGeAlD
Dinoprostone—PTGER4—lymph node—testicular cancer	0.000572	0.00846	CbGeAlD
Dinoprostone—CYP11A1—gonad—testicular cancer	0.000565	0.00836	CbGeAlD
Dinoprostone—SLC51A—lymph node—testicular cancer	0.000561	0.00831	CbGeAlD
Dinoprostone—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000544	0.015	CbGpPWpGaD
Dinoprostone—PTGFR—testis—testicular cancer	0.000534	0.00791	CbGeAlD
Dinoprostone—PTGIR—female gonad—testicular cancer	0.00053	0.00786	CbGeAlD
Dinoprostone—ABCC4—Ectoderm Differentiation—TFAP2C—testicular cancer	0.000515	0.0142	CbGpPWpGaD
Dinoprostone—PTGER2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000504	0.0139	CbGpPWpGaD
Dinoprostone—PTGER3—lymph node—testicular cancer	0.000484	0.00717	CbGeAlD
Dinoprostone—SLCO1C1—testis—testicular cancer	0.000472	0.00699	CbGeAlD
Dinoprostone—PTGIR—testis—testicular cancer	0.00047	0.00697	CbGeAlD
Dinoprostone—SLCO3A1—female gonad—testicular cancer	0.000468	0.00693	CbGeAlD
Dinoprostone—PTGER4—GPCR ligand binding—INSL3—testicular cancer	0.000467	0.0128	CbGpPWpGaD
Dinoprostone—PTGER3—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000465	0.0128	CbGpPWpGaD
Dinoprostone—SLCO2A1—female gonad—testicular cancer	0.000464	0.00687	CbGeAlD
Dinoprostone—CYP11A1—female gonad—testicular cancer	0.000459	0.00679	CbGeAlD
Dinoprostone—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000453	0.0125	CbGpPWpGaD
Dinoprostone—ABCC4—NRF2 pathway—SLC2A6—testicular cancer	0.00045	0.0124	CbGpPWpGaD
Dinoprostone—SLC22A7—testis—testicular cancer	0.000447	0.00663	CbGeAlD
Dinoprostone—SLCO2B1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000429	0.0118	CbGpPWpGaD
Dinoprostone—ABCC5—female gonad—testicular cancer	0.000424	0.00628	CbGeAlD
Dinoprostone—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000423	0.0116	CbGpPWpGaD
Dinoprostone—HPGDS—lymph node—testicular cancer	0.000418	0.0062	CbGeAlD
Dinoprostone—SLCO3A1—testis—testicular cancer	0.000415	0.00615	CbGeAlD
Dinoprostone—SLCO2A1—testis—testicular cancer	0.000411	0.00609	CbGeAlD
Dinoprostone—CYP11A1—testis—testicular cancer	0.000407	0.00603	CbGeAlD
Dinoprostone—SLCO2A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000396	0.0109	CbGpPWpGaD
Dinoprostone—SLC22A11—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000388	0.0107	CbGpPWpGaD
Dinoprostone—PTGFR—lymph node—testicular cancer	0.000387	0.00573	CbGeAlD
Dinoprostone—PTGER2—GPCR ligand binding—INSL3—testicular cancer	0.000384	0.0106	CbGpPWpGaD
Dinoprostone—SLCO4A1—testis—testicular cancer	0.000378	0.0056	CbGeAlD
Dinoprostone—ABCC5—testis—testicular cancer	0.000376	0.00557	CbGeAlD
Dinoprostone—SLCO3A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000376	0.0103	CbGpPWpGaD
Dinoprostone—CYP19A1—gonad—testicular cancer	0.000367	0.00543	CbGeAlD
Dinoprostone—SLCO4A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000358	0.00986	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR ligand binding—INSL3—testicular cancer	0.000354	0.00974	CbGpPWpGaD
Dinoprostone—SLC22A7—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000352	0.00969	CbGpPWpGaD
Dinoprostone—PTGFR—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000348	0.00956	CbGpPWpGaD
Dinoprostone—SLCO1C1—lymph node—testicular cancer	0.000342	0.00507	CbGeAlD
Dinoprostone—PTGIR—lymph node—testicular cancer	0.000341	0.00505	CbGeAlD
Dinoprostone—PTGIR—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00034	0.00936	CbGpPWpGaD
Dinoprostone—PTGER1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00034	0.00936	CbGpPWpGaD
Dinoprostone—SLCO2B1—female gonad—testicular cancer	0.000332	0.00492	CbGeAlD
Dinoprostone—SLCO3A1—lymph node—testicular cancer	0.000301	0.00446	CbGeAlD
Dinoprostone—SLCO1C1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.0003	0.00826	CbGpPWpGaD
Dinoprostone—SLCO2A1—lymph node—testicular cancer	0.000298	0.00441	CbGeAlD
Dinoprostone—CYP19A1—female gonad—testicular cancer	0.000298	0.00441	CbGeAlD
Dinoprostone—SLC22A8—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000296	0.00815	CbGpPWpGaD
Dinoprostone—CYP11A1—lymph node—testicular cancer	0.000295	0.00437	CbGeAlD
Dinoprostone—SLCO2B1—testis—testicular cancer	0.000294	0.00436	CbGeAlD
Dinoprostone—ABCC4—female gonad—testicular cancer	0.000294	0.00435	CbGeAlD
Dinoprostone—SLCO4A1—lymph node—testicular cancer	0.000274	0.00406	CbGeAlD
Dinoprostone—ABCC5—lymph node—testicular cancer	0.000273	0.00404	CbGeAlD
Dinoprostone—SLCO1A2—testis—testicular cancer	0.000271	0.00401	CbGeAlD
Dinoprostone—HPGDS—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000267	0.00734	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR ligand binding—INSL3—testicular cancer	0.000265	0.00728	CbGpPWpGaD
Dinoprostone—CYP19A1—testis—testicular cancer	0.000264	0.00392	CbGeAlD
Dinoprostone—PTGER4—GPCR downstream signaling—INSL3—testicular cancer	0.000264	0.00726	CbGpPWpGaD
Dinoprostone—SLCO1A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000263	0.00723	CbGpPWpGaD
Dinoprostone—ABCC4—testis—testicular cancer	0.000261	0.00386	CbGeAlD
Dinoprostone—PTGIR—GPCR ligand binding—INSL3—testicular cancer	0.000259	0.00713	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR ligand binding—INSL3—testicular cancer	0.000259	0.00713	CbGpPWpGaD
Dinoprostone—SLC22A6—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000247	0.0068	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—INSL3—testicular cancer	0.00024	0.00659	CbGpPWpGaD
Dinoprostone—SLCO1B1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000225	0.00619	CbGpPWpGaD
Dinoprostone—SLCO2B1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000218	0.00599	CbGpPWpGaD
Dinoprostone—PTGER2—GPCR downstream signaling—INSL3—testicular cancer	0.000217	0.00596	CbGpPWpGaD
Dinoprostone—SLCO2B1—lymph node—testicular cancer	0.000213	0.00316	CbGeAlD
Dinoprostone—ABCC5—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000208	0.00573	CbGpPWpGaD
Dinoprostone—SLC22A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000206	0.00567	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR downstream signaling—INSL3—testicular cancer	0.0002	0.0055	CbGpPWpGaD
Dinoprostone—SLC22A11—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000197	0.00543	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—INSL3—testicular cancer	0.000197	0.00541	CbGpPWpGaD
Dinoprostone—SLC22A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000192	0.00528	CbGpPWpGaD
Dinoprostone—CYP19A1—lymph node—testicular cancer	0.000192	0.00284	CbGeAlD
Dinoprostone—ABCC4—lymph node—testicular cancer	0.000189	0.0028	CbGeAlD
Dinoprostone—PTGER3—Signaling by GPCR—INSL3—testicular cancer	0.000182	0.005	CbGpPWpGaD
Dinoprostone—CYP11A1—Biological oxidations—HPGDS—testicular cancer	0.000181	0.00498	CbGpPWpGaD
Dinoprostone—SLC22A7—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000179	0.00492	CbGpPWpGaD
Dinoprostone—Chest pain—Bleomycin—testicular cancer	0.000173	0.00389	CcSEcCtD
Dinoprostone—Myocardial infarction—Etoposide—testicular cancer	0.000172	0.00387	CcSEcCtD
Dinoprostone—Abdominal pain—Chlorambucil—testicular cancer	0.000169	0.00381	CcSEcCtD
Dinoprostone—Body temperature increased—Chlorambucil—testicular cancer	0.000169	0.00381	CcSEcCtD
Dinoprostone—Pain—Vinblastine—testicular cancer	0.000168	0.00377	CcSEcCtD
Dinoprostone—Inflammation—Doxorubicin—testicular cancer	0.000168	0.00377	CcSEcCtD
Dinoprostone—Vaginal infection—Epirubicin—testicular cancer	0.000166	0.00373	CcSEcCtD
Dinoprostone—Anaphylactic shock—Bleomycin—testicular cancer	0.000166	0.00373	CcSEcCtD
Dinoprostone—Vision blurred—Ifosfamide—testicular cancer	0.000164	0.00368	CcSEcCtD
Dinoprostone—Vaginal inflammation—Doxorubicin—testicular cancer	0.000163	0.00366	CcSEcCtD
Dinoprostone—Hiccups—Doxorubicin—testicular cancer	0.000163	0.00366	CcSEcCtD
Dinoprostone—Cramps of lower extremities—Epirubicin—testicular cancer	0.000161	0.00363	CcSEcCtD
Dinoprostone—Myalgia—Dactinomycin—testicular cancer	0.000161	0.00362	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Vinblastine—testicular cancer	0.00016	0.00361	CcSEcCtD
Dinoprostone—Flushing—Cisplatin—testicular cancer	0.00016	0.00359	CcSEcCtD
Dinoprostone—Hypersensitivity—Chlorambucil—testicular cancer	0.000158	0.00355	CcSEcCtD
Dinoprostone—Immune system disorder—Cisplatin—testicular cancer	0.000155	0.00349	CcSEcCtD
Dinoprostone—Abdominal pain—Vinblastine—testicular cancer	0.000155	0.00349	CcSEcCtD
Dinoprostone—Hypotension—Bleomycin—testicular cancer	0.000155	0.00348	CcSEcCtD
Dinoprostone—Hypertonia—Epirubicin—testicular cancer	0.000154	0.00346	CcSEcCtD
Dinoprostone—Asthenia—Chlorambucil—testicular cancer	0.000154	0.00345	CcSEcCtD
Dinoprostone—Arrhythmia—Cisplatin—testicular cancer	0.000154	0.00345	CcSEcCtD
Dinoprostone—Vaginal infection—Doxorubicin—testicular cancer	0.000154	0.00345	CcSEcCtD
Dinoprostone—Cough—Ifosfamide—testicular cancer	0.000151	0.0034	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.000151	0.00339	CcSEcCtD
Dinoprostone—SLC22A8—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00015	0.00414	CbGpPWpGaD
Dinoprostone—Hypertension—Ifosfamide—testicular cancer	0.00015	0.00337	CcSEcCtD
Dinoprostone—PTGFR—GPCR downstream signaling—INSL3—testicular cancer	0.00015	0.00411	CbGpPWpGaD
Dinoprostone—Cramps of lower extremities—Doxorubicin—testicular cancer	0.000149	0.00336	CcSEcCtD
Dinoprostone—Paraesthesia—Bleomycin—testicular cancer	0.000149	0.00335	CcSEcCtD
Dinoprostone—Dyspnoea—Bleomycin—testicular cancer	0.000148	0.00332	CcSEcCtD
Dinoprostone—Myalgia—Ifosfamide—testicular cancer	0.000148	0.00332	CcSEcCtD
Dinoprostone—Chest pain—Ifosfamide—testicular cancer	0.000148	0.00332	CcSEcCtD
Dinoprostone—Arthralgia—Ifosfamide—testicular cancer	0.000148	0.00332	CcSEcCtD
Dinoprostone—Diarrhoea—Chlorambucil—testicular cancer	0.000147	0.00329	CcSEcCtD
Dinoprostone—PTGER1—GPCR downstream signaling—INSL3—testicular cancer	0.000146	0.00403	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—INSL3—testicular cancer	0.000146	0.00403	CbGpPWpGaD
Dinoprostone—Flushing—Etoposide—testicular cancer	0.000146	0.00329	CcSEcCtD
Dinoprostone—Hypersensitivity—Vinblastine—testicular cancer	0.000145	0.00325	CcSEcCtD
Dinoprostone—ABCC4—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000144	0.00397	CbGpPWpGaD
Dinoprostone—Muscle spasms—Cisplatin—testicular cancer	0.000144	0.00323	CcSEcCtD
Dinoprostone—Angiopathy—Etoposide—testicular cancer	0.000143	0.00321	CcSEcCtD
Dinoprostone—Hypertonia—Doxorubicin—testicular cancer	0.000143	0.0032	CcSEcCtD
Dinoprostone—Immune system disorder—Etoposide—testicular cancer	0.000142	0.0032	CcSEcCtD
Dinoprostone—Pain—Bleomycin—testicular cancer	0.000142	0.00319	CcSEcCtD
Dinoprostone—Anaphylactic shock—Ifosfamide—testicular cancer	0.000142	0.00318	CcSEcCtD
Dinoprostone—PTGER4—Signaling Pathways—INSL3—testicular cancer	0.000142	0.0039	CbGpPWpGaD
Dinoprostone—Eye pain—Epirubicin—testicular cancer	0.000141	0.00318	CcSEcCtD
Dinoprostone—Chills—Etoposide—testicular cancer	0.000141	0.00318	CcSEcCtD
Dinoprostone—Vision blurred—Cisplatin—testicular cancer	0.000141	0.00317	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Methotrexate—testicular cancer	0.000141	0.00317	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000141	0.00317	CcSEcCtD
Dinoprostone—Asthenia—Vinblastine—testicular cancer	0.000141	0.00317	CcSEcCtD
Dinoprostone—Tremor—Cisplatin—testicular cancer	0.00014	0.00315	CcSEcCtD
Dinoprostone—Hyperhidrosis—Ifosfamide—testicular cancer	0.000137	0.00308	CcSEcCtD
Dinoprostone—Hot flush—Epirubicin—testicular cancer	0.000136	0.00307	CcSEcCtD
Dinoprostone—Vomiting—Chlorambucil—testicular cancer	0.000136	0.00306	CcSEcCtD
Dinoprostone—PTGFR—Signaling by GPCR—INSL3—testicular cancer	0.000136	0.00374	CbGpPWpGaD
Dinoprostone—Menopausal symptoms—Epirubicin—testicular cancer	0.000135	0.00304	CcSEcCtD
Dinoprostone—Diarrhoea—Vinblastine—testicular cancer	0.000134	0.00302	CcSEcCtD
Dinoprostone—SLCO1A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000134	0.00368	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—INSL3—testicular cancer	0.000133	0.00366	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—INSL3—testicular cancer	0.000133	0.00366	CbGpPWpGaD
Dinoprostone—Back pain—Etoposide—testicular cancer	0.000133	0.00298	CcSEcCtD
Dinoprostone—Hypotension—Ifosfamide—testicular cancer	0.000132	0.00298	CcSEcCtD
Dinoprostone—Pain—Dactinomycin—testicular cancer	0.000132	0.00297	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Epirubicin—testicular cancer	0.000132	0.00296	CcSEcCtD
Dinoprostone—Muscle spasms—Etoposide—testicular cancer	0.000132	0.00296	CcSEcCtD
Dinoprostone—Body temperature increased—Bleomycin—testicular cancer	0.000131	0.00295	CcSEcCtD
Dinoprostone—Eye pain—Doxorubicin—testicular cancer	0.000131	0.00294	CcSEcCtD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00013	0.00359	CbGpPWpGaD
Dinoprostone—Dizziness—Vinblastine—testicular cancer	0.00013	0.00292	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.000129	0.0029	CcSEcCtD
Dinoprostone—Myalgia—Cisplatin—testicular cancer	0.000127	0.00286	CcSEcCtD
Dinoprostone—Nausea—Chlorambucil—testicular cancer	0.000127	0.00286	CcSEcCtD
Dinoprostone—Paraesthesia—Ifosfamide—testicular cancer	0.000127	0.00286	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000126	0.00284	CcSEcCtD
Dinoprostone—Dyspnoea—Ifosfamide—testicular cancer	0.000126	0.00284	CcSEcCtD
Dinoprostone—Hot flush—Doxorubicin—testicular cancer	0.000126	0.00284	CcSEcCtD
Dinoprostone—SLC22A6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000126	0.00345	CbGpPWpGaD
Dinoprostone—Menopausal symptoms—Doxorubicin—testicular cancer	0.000125	0.00281	CcSEcCtD
Dinoprostone—Vomiting—Vinblastine—testicular cancer	0.000125	0.0028	CcSEcCtD
Dinoprostone—Headache—Vinblastine—testicular cancer	0.000123	0.00276	CcSEcCtD
Dinoprostone—Body temperature increased—Dactinomycin—testicular cancer	0.000122	0.00275	CcSEcCtD
Dinoprostone—Abdominal pain—Dactinomycin—testicular cancer	0.000122	0.00275	CcSEcCtD
Dinoprostone—Anaphylactic shock—Cisplatin—testicular cancer	0.000122	0.00275	CcSEcCtD
Dinoprostone—Hypersensitivity—Bleomycin—testicular cancer	0.000122	0.00275	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Doxorubicin—testicular cancer	0.000122	0.00274	CcSEcCtD
Dinoprostone—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000122	0.00335	CbGpPWpGaD
Dinoprostone—Cardiac arrest—Epirubicin—testicular cancer	0.000121	0.00273	CcSEcCtD
Dinoprostone—Pain—Ifosfamide—testicular cancer	0.000121	0.00272	CcSEcCtD
Dinoprostone—Loss of consciousness—Etoposide—testicular cancer	0.00012	0.00271	CcSEcCtD
Dinoprostone—CYP19A1—Biological oxidations—HPGDS—testicular cancer	0.00012	0.0033	CbGpPWpGaD
Dinoprostone—Cough—Etoposide—testicular cancer	0.00012	0.00269	CcSEcCtD
Dinoprostone—Tachycardia—Cisplatin—testicular cancer	0.000119	0.00268	CcSEcCtD
Dinoprostone—Asthenia—Bleomycin—testicular cancer	0.000119	0.00267	CcSEcCtD
Dinoprostone—Dehydration—Epirubicin—testicular cancer	0.000119	0.00267	CcSEcCtD
Dinoprostone—Hypertension—Etoposide—testicular cancer	0.000118	0.00266	CcSEcCtD
Dinoprostone—Hyperhidrosis—Cisplatin—testicular cancer	0.000118	0.00265	CcSEcCtD
Dinoprostone—Asthma—Methotrexate—testicular cancer	0.000118	0.00265	CcSEcCtD
Dinoprostone—Chest pain—Etoposide—testicular cancer	0.000117	0.00262	CcSEcCtD
Dinoprostone—Nausea—Vinblastine—testicular cancer	0.000117	0.00262	CcSEcCtD
Dinoprostone—PTGER2—Signaling Pathways—INSL3—testicular cancer	0.000116	0.0032	CbGpPWpGaD
Dinoprostone—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000116	0.0026	CcSEcCtD
Dinoprostone—SLCO1B1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000114	0.00314	CbGpPWpGaD
Dinoprostone—Hypotension—Cisplatin—testicular cancer	0.000114	0.00257	CcSEcCtD
Dinoprostone—Hypersensitivity—Dactinomycin—testicular cancer	0.000114	0.00256	CcSEcCtD
Dinoprostone—Cardiac arrest—Doxorubicin—testicular cancer	0.000112	0.00252	CcSEcCtD
Dinoprostone—Abdominal pain—Ifosfamide—testicular cancer	0.000112	0.00252	CcSEcCtD
Dinoprostone—Body temperature increased—Ifosfamide—testicular cancer	0.000112	0.00252	CcSEcCtD
Dinoprostone—Anaphylactic shock—Etoposide—testicular cancer	0.000112	0.00251	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000111	0.0025	CcSEcCtD
Dinoprostone—Asthenia—Dactinomycin—testicular cancer	0.000111	0.00249	CcSEcCtD
Dinoprostone—Asthma—Epirubicin—testicular cancer	0.00011	0.00248	CcSEcCtD
Dinoprostone—Dehydration—Doxorubicin—testicular cancer	0.00011	0.00247	CcSEcCtD
Dinoprostone—Paraesthesia—Cisplatin—testicular cancer	0.00011	0.00246	CcSEcCtD
Dinoprostone—Tachycardia—Etoposide—testicular cancer	0.000109	0.00245	CcSEcCtD
Dinoprostone—Dyspnoea—Cisplatin—testicular cancer	0.000109	0.00245	CcSEcCtD
Dinoprostone—Hyperhidrosis—Etoposide—testicular cancer	0.000108	0.00243	CcSEcCtD
Dinoprostone—PTGER3—Signaling Pathways—INSL3—testicular cancer	0.000107	0.00295	CbGpPWpGaD
Dinoprostone—Diarrhoea—Dactinomycin—testicular cancer	0.000106	0.00238	CcSEcCtD
Dinoprostone—Vomiting—Bleomycin—testicular cancer	0.000105	0.00237	CcSEcCtD
Dinoprostone—SLC22A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000105	0.00288	CbGpPWpGaD
Dinoprostone—Hypotension—Etoposide—testicular cancer	0.000105	0.00235	CcSEcCtD
Dinoprostone—Rash—Bleomycin—testicular cancer	0.000105	0.00235	CcSEcCtD
Dinoprostone—Pain—Cisplatin—testicular cancer	0.000104	0.00235	CcSEcCtD
Dinoprostone—Dermatitis—Bleomycin—testicular cancer	0.000104	0.00235	CcSEcCtD
Dinoprostone—Hypersensitivity—Ifosfamide—testicular cancer	0.000104	0.00235	CcSEcCtD
Dinoprostone—Asthma—Doxorubicin—testicular cancer	0.000102	0.00229	CcSEcCtD
Dinoprostone—Asthenia—Ifosfamide—testicular cancer	0.000102	0.00228	CcSEcCtD
Dinoprostone—Paraesthesia—Etoposide—testicular cancer	0.0001	0.00226	CcSEcCtD
Dinoprostone—Dyspnoea—Etoposide—testicular cancer	9.97e-05	0.00224	CcSEcCtD
Dinoprostone—Nausea—Bleomycin—testicular cancer	9.84e-05	0.00221	CcSEcCtD
Dinoprostone—Vomiting—Dactinomycin—testicular cancer	9.83e-05	0.00221	CcSEcCtD
Dinoprostone—SLC22A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	9.76e-05	0.00268	CbGpPWpGaD
Dinoprostone—Rash—Dactinomycin—testicular cancer	9.75e-05	0.00219	CcSEcCtD
Dinoprostone—Diarrhoea—Ifosfamide—testicular cancer	9.69e-05	0.00218	CcSEcCtD
Dinoprostone—CYP19A1—Integrated Breast Cancer Pathway—STK11—testicular cancer	9.68e-05	0.00266	CbGpPWpGaD
Dinoprostone—Body temperature increased—Cisplatin—testicular cancer	9.65e-05	0.00217	CcSEcCtD
Dinoprostone—Pain—Etoposide—testicular cancer	9.57e-05	0.00215	CcSEcCtD
Dinoprostone—Dizziness—Ifosfamide—testicular cancer	9.37e-05	0.00211	CcSEcCtD
Dinoprostone—Pharyngitis—Methotrexate—testicular cancer	9.36e-05	0.0021	CcSEcCtD
Dinoprostone—Nausea—Dactinomycin—testicular cancer	9.18e-05	0.00206	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Etoposide—testicular cancer	9.15e-05	0.00206	CcSEcCtD
Dinoprostone—Vomiting—Ifosfamide—testicular cancer	9.01e-05	0.00202	CcSEcCtD
Dinoprostone—Hypersensitivity—Cisplatin—testicular cancer	9e-05	0.00202	CcSEcCtD
Dinoprostone—Rash—Ifosfamide—testicular cancer	8.93e-05	0.00201	CcSEcCtD
Dinoprostone—Dermatitis—Ifosfamide—testicular cancer	8.92e-05	0.00201	CcSEcCtD
Dinoprostone—Abdominal pain—Etoposide—testicular cancer	8.84e-05	0.00199	CcSEcCtD
Dinoprostone—Body temperature increased—Etoposide—testicular cancer	8.84e-05	0.00199	CcSEcCtD
Dinoprostone—Asthenia—Cisplatin—testicular cancer	8.76e-05	0.00197	CcSEcCtD
Dinoprostone—Pharyngitis—Epirubicin—testicular cancer	8.76e-05	0.00197	CcSEcCtD
Dinoprostone—Angiopathy—Methotrexate—testicular cancer	8.56e-05	0.00192	CcSEcCtD
Dinoprostone—Immune system disorder—Methotrexate—testicular cancer	8.52e-05	0.00192	CcSEcCtD
Dinoprostone—Chills—Methotrexate—testicular cancer	8.46e-05	0.0019	CcSEcCtD
Dinoprostone—Nausea—Ifosfamide—testicular cancer	8.41e-05	0.00189	CcSEcCtD
Dinoprostone—Diarrhoea—Cisplatin—testicular cancer	8.36e-05	0.00188	CcSEcCtD
Dinoprostone—Hypersensitivity—Etoposide—testicular cancer	8.24e-05	0.00185	CcSEcCtD
Dinoprostone—Flushing—Epirubicin—testicular cancer	8.19e-05	0.00184	CcSEcCtD
Dinoprostone—Pharyngitis—Doxorubicin—testicular cancer	8.11e-05	0.00182	CcSEcCtD
Dinoprostone—Asthenia—Etoposide—testicular cancer	8.03e-05	0.0018	CcSEcCtD
Dinoprostone—PTGFR—Signaling Pathways—INSL3—testicular cancer	8.02e-05	0.00221	CbGpPWpGaD
Dinoprostone—Angiopathy—Epirubicin—testicular cancer	8.01e-05	0.0018	CcSEcCtD
Dinoprostone—Immune system disorder—Epirubicin—testicular cancer	7.97e-05	0.00179	CcSEcCtD
Dinoprostone—Back pain—Methotrexate—testicular cancer	7.94e-05	0.00179	CcSEcCtD
Dinoprostone—Chills—Epirubicin—testicular cancer	7.92e-05	0.00178	CcSEcCtD
Dinoprostone—Arrhythmia—Epirubicin—testicular cancer	7.89e-05	0.00177	CcSEcCtD
Dinoprostone—PTGIR—Signaling Pathways—INSL3—testicular cancer	7.85e-05	0.00216	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—INSL3—testicular cancer	7.85e-05	0.00216	CbGpPWpGaD
Dinoprostone—Vomiting—Cisplatin—testicular cancer	7.76e-05	0.00175	CcSEcCtD
Dinoprostone—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	7.76e-05	0.00213	CbGpPWpGaD
Dinoprostone—Vision blurred—Methotrexate—testicular cancer	7.74e-05	0.00174	CcSEcCtD
Dinoprostone—Rash—Cisplatin—testicular cancer	7.7e-05	0.00173	CcSEcCtD
Dinoprostone—Dermatitis—Cisplatin—testicular cancer	7.69e-05	0.00173	CcSEcCtD
Dinoprostone—Diarrhoea—Etoposide—testicular cancer	7.65e-05	0.00172	CcSEcCtD
Dinoprostone—Flushing—Doxorubicin—testicular cancer	7.58e-05	0.0017	CcSEcCtD
Dinoprostone—Tension—Epirubicin—testicular cancer	7.54e-05	0.0017	CcSEcCtD
Dinoprostone—Back pain—Epirubicin—testicular cancer	7.43e-05	0.00167	CcSEcCtD
Dinoprostone—Angiopathy—Doxorubicin—testicular cancer	7.41e-05	0.00167	CcSEcCtD
Dinoprostone—Dizziness—Etoposide—testicular cancer	7.4e-05	0.00166	CcSEcCtD
Dinoprostone—Muscle spasms—Epirubicin—testicular cancer	7.39e-05	0.00166	CcSEcCtD
Dinoprostone—Immune system disorder—Doxorubicin—testicular cancer	7.38e-05	0.00166	CcSEcCtD
Dinoprostone—Chills—Doxorubicin—testicular cancer	7.33e-05	0.00165	CcSEcCtD
Dinoprostone—Arrhythmia—Doxorubicin—testicular cancer	7.3e-05	0.00164	CcSEcCtD
Dinoprostone—Nausea—Cisplatin—testicular cancer	7.25e-05	0.00163	CcSEcCtD
Dinoprostone—Vision blurred—Epirubicin—testicular cancer	7.24e-05	0.00163	CcSEcCtD
Dinoprostone—Cough—Methotrexate—testicular cancer	7.16e-05	0.00161	CcSEcCtD
Dinoprostone—Vomiting—Etoposide—testicular cancer	7.11e-05	0.0016	CcSEcCtD
Dinoprostone—Rash—Etoposide—testicular cancer	7.05e-05	0.00159	CcSEcCtD
Dinoprostone—Dermatitis—Etoposide—testicular cancer	7.05e-05	0.00158	CcSEcCtD
Dinoprostone—Headache—Etoposide—testicular cancer	7.01e-05	0.00158	CcSEcCtD
Dinoprostone—Arthralgia—Methotrexate—testicular cancer	6.99e-05	0.00157	CcSEcCtD
Dinoprostone—Myalgia—Methotrexate—testicular cancer	6.99e-05	0.00157	CcSEcCtD
Dinoprostone—Chest pain—Methotrexate—testicular cancer	6.99e-05	0.00157	CcSEcCtD
Dinoprostone—Tension—Doxorubicin—testicular cancer	6.98e-05	0.00157	CcSEcCtD
Dinoprostone—CYP11A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.96e-05	0.00191	CbGpPWpGaD
Dinoprostone—Syncope—Epirubicin—testicular cancer	6.89e-05	0.00155	CcSEcCtD
Dinoprostone—Back pain—Doxorubicin—testicular cancer	6.88e-05	0.00155	CcSEcCtD
Dinoprostone—Muscle spasms—Doxorubicin—testicular cancer	6.84e-05	0.00154	CcSEcCtD
Dinoprostone—Loss of consciousness—Epirubicin—testicular cancer	6.75e-05	0.00152	CcSEcCtD
Dinoprostone—Cough—Epirubicin—testicular cancer	6.71e-05	0.00151	CcSEcCtD
Dinoprostone—Anaphylactic shock—Methotrexate—testicular cancer	6.7e-05	0.00151	CcSEcCtD
Dinoprostone—Vision blurred—Doxorubicin—testicular cancer	6.7e-05	0.00151	CcSEcCtD
Dinoprostone—Nausea—Etoposide—testicular cancer	6.65e-05	0.00149	CcSEcCtD
Dinoprostone—Hypertension—Epirubicin—testicular cancer	6.63e-05	0.00149	CcSEcCtD
Dinoprostone—Arthralgia—Epirubicin—testicular cancer	6.54e-05	0.00147	CcSEcCtD
Dinoprostone—Myalgia—Epirubicin—testicular cancer	6.54e-05	0.00147	CcSEcCtD
Dinoprostone—Chest pain—Epirubicin—testicular cancer	6.54e-05	0.00147	CcSEcCtD
Dinoprostone—Hyperhidrosis—Methotrexate—testicular cancer	6.48e-05	0.00146	CcSEcCtD
Dinoprostone—Syncope—Doxorubicin—testicular cancer	6.38e-05	0.00143	CcSEcCtD
Dinoprostone—Anaphylactic shock—Epirubicin—testicular cancer	6.27e-05	0.00141	CcSEcCtD
Dinoprostone—Hypotension—Methotrexate—testicular cancer	6.26e-05	0.00141	CcSEcCtD
Dinoprostone—Loss of consciousness—Doxorubicin—testicular cancer	6.25e-05	0.0014	CcSEcCtD
Dinoprostone—Cough—Doxorubicin—testicular cancer	6.2e-05	0.00139	CcSEcCtD
Dinoprostone—Shock—Epirubicin—testicular cancer	6.17e-05	0.00139	CcSEcCtD
Dinoprostone—Hypertension—Doxorubicin—testicular cancer	6.14e-05	0.00138	CcSEcCtD
Dinoprostone—Tachycardia—Epirubicin—testicular cancer	6.12e-05	0.00138	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Methotrexate—testicular cancer	6.11e-05	0.00137	CcSEcCtD
Dinoprostone—Hyperhidrosis—Epirubicin—testicular cancer	6.06e-05	0.00136	CcSEcCtD
Dinoprostone—Chest pain—Doxorubicin—testicular cancer	6.05e-05	0.00136	CcSEcCtD
Dinoprostone—Myalgia—Doxorubicin—testicular cancer	6.05e-05	0.00136	CcSEcCtD
Dinoprostone—Arthralgia—Doxorubicin—testicular cancer	6.05e-05	0.00136	CcSEcCtD
Dinoprostone—Paraesthesia—Methotrexate—testicular cancer	6.02e-05	0.00135	CcSEcCtD
Dinoprostone—Dyspnoea—Methotrexate—testicular cancer	5.97e-05	0.00134	CcSEcCtD
Dinoprostone—Hypotension—Epirubicin—testicular cancer	5.86e-05	0.00132	CcSEcCtD
Dinoprostone—Anaphylactic shock—Doxorubicin—testicular cancer	5.8e-05	0.0013	CcSEcCtD
Dinoprostone—Pain—Methotrexate—testicular cancer	5.73e-05	0.00129	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Epirubicin—testicular cancer	5.71e-05	0.00128	CcSEcCtD
Dinoprostone—Shock—Doxorubicin—testicular cancer	5.71e-05	0.00128	CcSEcCtD
Dinoprostone—Tachycardia—Doxorubicin—testicular cancer	5.66e-05	0.00127	CcSEcCtD
Dinoprostone—Paraesthesia—Epirubicin—testicular cancer	5.63e-05	0.00127	CcSEcCtD
Dinoprostone—Hyperhidrosis—Doxorubicin—testicular cancer	5.61e-05	0.00126	CcSEcCtD
Dinoprostone—Dyspnoea—Epirubicin—testicular cancer	5.59e-05	0.00126	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Methotrexate—testicular cancer	5.48e-05	0.00123	CcSEcCtD
Dinoprostone—Hypotension—Doxorubicin—testicular cancer	5.42e-05	0.00122	CcSEcCtD
Dinoprostone—Pain—Epirubicin—testicular cancer	5.36e-05	0.00121	CcSEcCtD
Dinoprostone—Abdominal pain—Methotrexate—testicular cancer	5.3e-05	0.00119	CcSEcCtD
Dinoprostone—Body temperature increased—Methotrexate—testicular cancer	5.3e-05	0.00119	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Doxorubicin—testicular cancer	5.29e-05	0.00119	CcSEcCtD
Dinoprostone—Paraesthesia—Doxorubicin—testicular cancer	5.21e-05	0.00117	CcSEcCtD
Dinoprostone—Dyspnoea—Doxorubicin—testicular cancer	5.17e-05	0.00116	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Epirubicin—testicular cancer	5.13e-05	0.00115	CcSEcCtD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	5.1e-05	0.0014	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—STK11—testicular cancer	4.97e-05	0.00137	CbGpPWpGaD
Dinoprostone—Pain—Doxorubicin—testicular cancer	4.96e-05	0.00112	CcSEcCtD
Dinoprostone—Body temperature increased—Epirubicin—testicular cancer	4.96e-05	0.00111	CcSEcCtD
Dinoprostone—Abdominal pain—Epirubicin—testicular cancer	4.96e-05	0.00111	CcSEcCtD
Dinoprostone—Hypersensitivity—Methotrexate—testicular cancer	4.94e-05	0.00111	CcSEcCtD
Dinoprostone—Asthenia—Methotrexate—testicular cancer	4.81e-05	0.00108	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Doxorubicin—testicular cancer	4.74e-05	0.00107	CcSEcCtD
Dinoprostone—Hypersensitivity—Epirubicin—testicular cancer	4.62e-05	0.00104	CcSEcCtD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.61e-05	0.00127	CbGpPWpGaD
Dinoprostone—Body temperature increased—Doxorubicin—testicular cancer	4.59e-05	0.00103	CcSEcCtD
Dinoprostone—Abdominal pain—Doxorubicin—testicular cancer	4.59e-05	0.00103	CcSEcCtD
Dinoprostone—Diarrhoea—Methotrexate—testicular cancer	4.58e-05	0.00103	CcSEcCtD
Dinoprostone—CYP1A2—Biological oxidations—HPGDS—testicular cancer	4.54e-05	0.00125	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—H2AFZ—testicular cancer	4.53e-05	0.00125	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—STK11—testicular cancer	4.51e-05	0.00124	CbGpPWpGaD
Dinoprostone—Asthenia—Epirubicin—testicular cancer	4.5e-05	0.00101	CcSEcCtD
Dinoprostone—Dizziness—Methotrexate—testicular cancer	4.43e-05	0.000996	CcSEcCtD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.36e-05	0.0012	CbGpPWpGaD
Dinoprostone—Diarrhoea—Epirubicin—testicular cancer	4.29e-05	0.000965	CcSEcCtD
Dinoprostone—Hypersensitivity—Doxorubicin—testicular cancer	4.28e-05	0.000961	CcSEcCtD
Dinoprostone—Vomiting—Methotrexate—testicular cancer	4.26e-05	0.000958	CcSEcCtD
Dinoprostone—Rash—Methotrexate—testicular cancer	4.23e-05	0.00095	CcSEcCtD
Dinoprostone—Dermatitis—Methotrexate—testicular cancer	4.22e-05	0.000949	CcSEcCtD
Dinoprostone—Headache—Methotrexate—testicular cancer	4.2e-05	0.000944	CcSEcCtD
Dinoprostone—PTGER4—Signaling Pathways—KITLG—testicular cancer	4.17e-05	0.00115	CbGpPWpGaD
Dinoprostone—Asthenia—Doxorubicin—testicular cancer	4.16e-05	0.000936	CcSEcCtD
Dinoprostone—Dizziness—Epirubicin—testicular cancer	4.15e-05	0.000932	CcSEcCtD
Dinoprostone—Vomiting—Epirubicin—testicular cancer	3.99e-05	0.000896	CcSEcCtD
Dinoprostone—Nausea—Methotrexate—testicular cancer	3.98e-05	0.000895	CcSEcCtD
Dinoprostone—Diarrhoea—Doxorubicin—testicular cancer	3.97e-05	0.000892	CcSEcCtD
Dinoprostone—Rash—Epirubicin—testicular cancer	3.95e-05	0.000889	CcSEcCtD
Dinoprostone—Dermatitis—Epirubicin—testicular cancer	3.95e-05	0.000888	CcSEcCtD
Dinoprostone—Headache—Epirubicin—testicular cancer	3.93e-05	0.000883	CcSEcCtD
Dinoprostone—Dizziness—Doxorubicin—testicular cancer	3.84e-05	0.000863	CcSEcCtD
Dinoprostone—Nausea—Epirubicin—testicular cancer	3.72e-05	0.000837	CcSEcCtD
Dinoprostone—PTGER2—Signaling Pathways—H2AFZ—testicular cancer	3.72e-05	0.00102	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—STK11—testicular cancer	3.7e-05	0.00102	CbGpPWpGaD
Dinoprostone—Vomiting—Doxorubicin—testicular cancer	3.69e-05	0.000829	CcSEcCtD
Dinoprostone—Rash—Doxorubicin—testicular cancer	3.66e-05	0.000822	CcSEcCtD
Dinoprostone—Dermatitis—Doxorubicin—testicular cancer	3.66e-05	0.000822	CcSEcCtD
Dinoprostone—Headache—Doxorubicin—testicular cancer	3.64e-05	0.000817	CcSEcCtD
Dinoprostone—ABCC5—Metabolism—HPGDS—testicular cancer	3.54e-05	0.000973	CbGpPWpGaD
Dinoprostone—Nausea—Doxorubicin—testicular cancer	3.45e-05	0.000775	CcSEcCtD
Dinoprostone—PTGER3—Signaling Pathways—H2AFZ—testicular cancer	3.44e-05	0.000945	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—KITLG—testicular cancer	3.42e-05	0.000942	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—STK11—testicular cancer	3.42e-05	0.000939	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—KITLG—testicular cancer	3.16e-05	0.000869	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—FGFR3—testicular cancer	3.1e-05	0.000852	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—HPGDS—testicular cancer	3.1e-05	0.000852	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—H2AFZ—testicular cancer	3.09e-05	0.000849	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—KIT—testicular cancer	2.85e-05	0.000783	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—KITLG—testicular cancer	2.84e-05	0.000781	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—STK11—testicular cancer	2.57e-05	0.000707	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—H2AFZ—testicular cancer	2.57e-05	0.000707	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—STK11—testicular cancer	2.55e-05	0.000703	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—FGFR3—testicular cancer	2.55e-05	0.0007	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—H2AFZ—testicular cancer	2.51e-05	0.000692	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—H2AFZ—testicular cancer	2.51e-05	0.000692	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—STK11—testicular cancer	2.5e-05	0.000688	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—STK11—testicular cancer	2.5e-05	0.000688	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—KITLG—testicular cancer	2.36e-05	0.00065	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—FGFR3—testicular cancer	2.35e-05	0.000646	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—KIT—testicular cancer	2.34e-05	0.000643	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—KITLG—testicular cancer	2.31e-05	0.000636	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—KITLG—testicular cancer	2.31e-05	0.000636	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—HPGDS—testicular cancer	2.27e-05	0.000625	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—STK11—testicular cancer	2.25e-05	0.000619	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—KIT—testicular cancer	2.16e-05	0.000593	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—FGFR3—testicular cancer	2.11e-05	0.000581	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—HPGDS—testicular cancer	2.05e-05	0.000565	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—HPGDS—testicular cancer	1.94e-05	0.000534	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—KIT—testicular cancer	1.94e-05	0.000533	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—HPGDS—testicular cancer	1.78e-05	0.00049	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—FGFR3—testicular cancer	1.76e-05	0.000483	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.74e-05	0.000479	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—FGFR3—testicular cancer	1.72e-05	0.000473	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—FGFR3—testicular cancer	1.72e-05	0.000473	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—HPGDS—testicular cancer	1.66e-05	0.000456	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—STK11—testicular cancer	1.65e-05	0.000454	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—KIT—testicular cancer	1.61e-05	0.000444	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—KIT—testicular cancer	1.58e-05	0.000434	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—KIT—testicular cancer	1.58e-05	0.000434	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—STK11—testicular cancer	1.49e-05	0.00041	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—STK11—testicular cancer	1.41e-05	0.000388	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—STK11—testicular cancer	1.29e-05	0.000356	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—STK11—testicular cancer	1.21e-05	0.000332	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—HPGDS—testicular cancer	7.76e-06	0.000214	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—STK11—testicular cancer	5.64e-06	0.000155	CbGpPWpGaD
